Return to search results.
Complete title: A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
|Research Study Number||2616.00|
|Principal Investigator||Roland Walter, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.